Who
Michael Nofi
Chief Financial Officer
Company insider
Files Form 4 as: Chief Financial Officer, Edgewise Therapeutics; Chief Accounting Officer, SpringWorks Therapeutics.
In numbers
- Trades disclosed
- 35
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 2 Dec 2019
- Last trade
- 12 Aug 2026
- Last filed
- 17 Aug 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 12 Aug 2026filed 17 Aug 2026 | EWTX Edgewise Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —48,750 at $0.00 | filing |
| 12 Aug 2026filed 17 Aug 2026 | EWTX Edgewise Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —48,750 at $0.00 | filing |
| 12 Aug 2026filed 14 Aug 2026 | EWTX Edgewise Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —24,375 at $0.00 | filing |
| 12 Aug 2026filed 14 Aug 2026 | EWTX Edgewise Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —48,750 at $0.00 | filing |
| 12 Aug 2026filed 14 Aug 2026 | EWTX Edgewise Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —24,375 at $0.00 | filing |
| 12 Aug 2026filed 14 Aug 2026 | EWTX Edgewise Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —48,750 at $0.00 | filing |
| 10 Nov 2025filed 13 Nov 2025 | EWTX Edgewise Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —43,750 at $0.00 | filing |
| 10 Nov 2025filed 13 Nov 2025 | EWTX Edgewise Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —262,500 at $0.00 | filing |
| 1 Jul 2025filed 2 Jul 2025 | SpringWorks Therapeuticsoption or derivative | SEC FORM 4 Code D | —8,661 | filing |
| 1 Jul 2025filed 2 Jul 2025 | SpringWorks Therapeuticsoption or derivative | SEC FORM 4 Code D | —78,300 | filing |
| 1 Jul 2025filed 2 Jul 2025 | SpringWorks Therapeuticsoption or derivative | SEC FORM 4 Code D | —65,000 | filing |
| 1 Jul 2025filed 2 Jul 2025 | SpringWorks Therapeuticsoption or derivative | SEC FORM 4 Code D | —40,000 | filing |
| 1 Jul 2025filed 2 Jul 2025 | SpringWorks Therapeuticsoption or derivative | SEC FORM 4 Code D | —20,246 | filing |
| 1 Jul 2025filed 2 Jul 2025 | SpringWorks Therapeutics | SEC FORM 4 Code D | —30,623 | filing |
| 10 Jan 2025filed 14 Jan 2025 | SpringWorks Therapeuticsoption or derivative | SEC FORM 4 Code A | —20,246 at $0.00 | filing |
| 10 Jan 2025filed 14 Jan 2025 | SpringWorks Therapeutics | SEC FORM 4 Code A | —6,929 at $0.00 | filing |
| 6 Jan 2025filed 7 Jan 2025 | SpringWorks Therapeutics | SEC FORM 4 Code F | $39K1,009 at $38.86 | filing |
| 5 Jan 2025filed 7 Jan 2025 | SpringWorks Therapeutics | SEC FORM 4 Code F | $62K1,636 at $38.19 | filing |
| 4 Jan 2025filed 7 Jan 2025 | SpringWorks Therapeutics | SEC FORM 4 Code F | $91K2,388 at $38.19 | filing |
| 8 Jan 2024filed 8 Jan 2024 | SpringWorks Therapeutics | SEC FORM 4 Code F | $44K1,063 at $41.53 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.